Recurrent somatic TET2 mutations in normal elderly individuals with clonal hematopoiesis

Lambert Busque, Jay P Patel, Maria E Figueroa, Aparna Vasanthakumar, Sylvie Provost, Zineb Hamilou, Luigina Mollica, Juan Li, Agnes Viale, Adriana Heguy, Maryam Hassimi, Nicholas Socci, Parva K Bhatt, Mithat Gonen, Christopher E Mason, Ari Melnick, Lucy A Godley, Cameron W Brennan, Omar Abdel-Wahab, Ross L Levine, Lambert Busque, Jay P Patel, Maria E Figueroa, Aparna Vasanthakumar, Sylvie Provost, Zineb Hamilou, Luigina Mollica, Juan Li, Agnes Viale, Adriana Heguy, Maryam Hassimi, Nicholas Socci, Parva K Bhatt, Mithat Gonen, Christopher E Mason, Ari Melnick, Lucy A Godley, Cameron W Brennan, Omar Abdel-Wahab, Ross L Levine

Abstract

Aging is characterized by clonal expansion of myeloid-biased hematopoietic stem cells and by increased risk of myeloid malignancies. Exome sequencing of three elderly females with clonal hematopoiesis, demonstrated by X-inactivation analysis, identified somatic TET2 mutations. Recurrence testing identified TET2 mutations in 10 out of 182 individuals with X-inactivation skewing. TET2 mutations were specific to individuals with clonal hematopoiesis without hematological malignancies and were associated with alterations in DNA methylation.

Figures

Figure 1. Somatic TET2 mutations are present…
Figure 1. Somatic TET2 mutations are present in normal elderly individuals with myeloid skewing and associated with epigenetic alterations
Exome sequencing identifies somatic TET2 mutation in myeloid cells of an elderly normal subject with non-random X-inactivation (A). LC/MS analysis reveals a decrease in 5-hmC with age and increased 5-mC in PMNs of elderly individuals with TET2 mutations (asterisk indicates p<0.05; arrowheads indicate comparator) (B). This is associated with site-specific hypermethylation and transcriptional silencing (C) in normal individuals with TET2 mutations as revealed by MassArray Epityper and qRT-PCR analysis in the PMNs of 6 TET2 wildtype and 6 mutant individuals. Error bars represent standard deviation relative to mean in panels B and C.

References

    1. Beerman I, Maloney WJ, Weissmann IL, Rossi DJ. Curr Opin Immunol. 2010;22:500.
    1. Beerman I, et al. Proc Natl Acad Sci U S A. 2010;107:5465.
    1. Busque L, et al. Blood. 1996;88:59.
    1. Gale RE, Fielding AK, Harrison CN, Linch DC. Br J Haematol. 1997;98:512.
    1. Busque L, Gilliland DG. Leukemia. 1998;12:128.
    1. Delhommeau F, et al. N Engl J Med. 2009;360:2289.
    1. Moran-Crusio K, et al. Cancer cell. 2011;20:11.
    1. Quivoron C, et al. Cancer cell. 2011;20:25.
    1. Li Z, et al. Blood. 2011
    1. Ko M, et al. Proc Natl Acad Sci U S A. 2011;108:14566.
    1. Tefferi A, et al. Leukemia. 2009;23:905.
    1. Ko M, et al. Nature. 2010;468:839.
    1. Figueroa ME, et al. Cancer Cell. 2010;18:553.

Source: PubMed

3
Tilaa